These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 28294487)

  • 1. Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study.
    Monforte V; Sintes H; López-Gallo C; Delgado M; Santos F; Zurbano F; Solé A; Gavaldá J; Borro JM; Redel-Montero J; Cifrian JM; Pastor A; Román A; Ussetti P
    Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28294487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients.
    Mabilangan C; Preiksaitis J; Cervera C;
    Transpl Infect Dis; 2018 Oct; 20(5):e12964. PubMed ID: 29981174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.
    Heldenbrand S; Li C; Cross RP; DePiero KA; Dick TB; Ferguson K; Kim M; Newkirk E; Park JM; Sudaria-Kerr J; Tichy EM; Ueda KR; Weng R; Wisniewski J; Gabardi S
    Transpl Infect Dis; 2016 Dec; 18(6):904-912. PubMed ID: 27639246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus infection in heart transplantation: A single center experience.
    Echenique IA; Angarone MP; Rich JD; Anderson AS; Stosor V
    Transpl Infect Dis; 2018 Aug; 20(4):e12896. PubMed ID: 29602266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients.
    Johansson I; Mårtensson G; Nyström U; Nasic S; Andersson R
    BMC Infect Dis; 2013 Dec; 13():582. PubMed ID: 24325216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
    Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
    Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose valganciclovir prophylaxis for cytomegalovirus in intermediate-risk (R+) renal transplant recipients: Single-center experience.
    Khan S; Fischman C; Huprikar S
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28940831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
    Reusing JO; Feitosa EB; Agena F; Pierrotti LC; Azevedo LSF; Kotton CN; David-Neto E
    Transpl Infect Dis; 2018 Oct; 20(5):e12929. PubMed ID: 29809309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
    Wiita AP; Roubinian N; Khan Y; Chin-Hong PV; Singer JP; Golden JA; Miller S
    Transpl Infect Dis; 2012 Jun; 14(3):248-58. PubMed ID: 22385394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
    Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
    J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of post-prophylaxis cytomegalovirus infection in lung transplant recipients.
    Jaamei N; Koutsokera A; Pasquier J; Mombelli M; Meylan P; Pascual M; Aubert JD; Manuel O
    Transpl Infect Dis; 2018 Aug; 20(4):e12893. PubMed ID: 29603543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis.
    Beam E; Lesnick T; Kremers W; Kennedy CC; Razonable RR
    Clin Transplant; 2016 Mar; 30(3):270-8. PubMed ID: 26701733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients.
    Monforte V; Lopez C; Santos F; Zurbano F; de la Torre M; Sole A; Gavalda J; Ussetti P; Lama R; Cifrian J; Borro JM; Pastor A; Len O; Bravo C; Roman A
    Am J Transplant; 2009 May; 9(5):1134-41. PubMed ID: 19344437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extending cytomegalovirus prophylaxis in high-risk (D+/R-) lung transplant recipients from 6 to 9 months reduces cytomegalovirus disease: A retrospective study.
    Herrera S; Khan B; Singer LG; Binnie M; Chaparro C; Chow CW; Martinu T; Tomlinson G; Keshavjee S; Husain S; Tikkanen JM
    Transpl Infect Dis; 2020 Aug; 22(4):e13277. PubMed ID: 32170813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.
    Fernández-Ruiz M; Arias M; Campistol JM; Navarro D; Gómez-Huertas E; Gómez-Márquez G; Díaz JM; Hernández D; Bernal-Blanco G; Cofan F; Jimeno L; Franco-Esteve A; González E; Moreso FJ; Gómez-Alamillo C; Mendiluce A; Luna-Huerta E; Aguado JM;
    Transpl Int; 2015 Sep; 28(9):1042-54. PubMed ID: 25864986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study.
    Avery RK; Silveira FP; Benedict K; Cleveland AA; Kauffman CA; Schuster MG; Dubberke ER; Husain S; Paterson DL; Chiller T; Pappas P
    Transpl Infect Dis; 2018 Jun; 20(3):e12877. PubMed ID: 29512935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
    Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients.
    Mabilangan C; Preiksaitis JK; Cervera C;
    Transpl Infect Dis; 2019 Feb; 21(1):e13015. PubMed ID: 30358023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
    Kuo HT; Ye X; Sampaio MS; Reddy P; Bunnapradist S
    Transplantation; 2010 Nov; 90(10):1091-8. PubMed ID: 20885340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.
    Fleming JN; Taber DJ; Weimert NA; Nadig S; McGillicuddy JW; Bratton CF; Baliga PK; Chavin KD
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.